Results 61 to 70 of about 1,288 (185)
Hope on the horizon: Novel fungal treatments in development [PDF]
, 2020 The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance.
Coler-Reilly, Ariella +3 more
core +1 more source
Advances in the Treatment of Invasive Fungal Disease [PDF]
, 2023 With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality.
An, Zhiqiang +2 more
core +1 more source
Emerging and Future Strategies in the Management of Recalcitrant Candida auris [PDF]
, 2022 Candida auris is an emerging, multi drug resistant fungal pathogen that has caused infectious outbreaks in over 45 countries since its first isolation over a decade ago, leading to in-hospital crude mortality rates as high as 72%.
Bandara, Nihal, Samaranayake, Lakshman
core +3 more sources
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306 [PDF]
, 2023 Background: Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ...
Angulo, David +10 more
core +1 more source
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]
, 2023 Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
De Rosa, Francesco Giuseppe +1 more
core +4 more sources
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source
BJOG: an International Journal of Obstetrics and Gynaecology, 2021 To evaluate the efficacy and safety of ibrexafungerp versus placebo for acute vulvovaginal candidiasis (VVC) treatment.
Ryan H. Sobel +8 more
semanticscholar +1 more source
Fungal Cell Wall: Emerging Antifungals and Drug Resistance
Frontiers in Microbiology, 2019 The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in human cells makes this component an attractive target for antifungal development. The host environment and antifungal stress can lead to cell wall modifications
Soraia L. Lima +2 more
doaj +1 more source
Candida auris: a quick review on identification, current treatments, and challenges [PDF]
, 2021 Candida auris is a novel and major fungal pathogen that has triggered several outbreaks in the last decade. The few drugs available to treat fungal diseases, the fact that this yeast has a high rate of multidrug resistance and the occurrence of ...
Brás, Susana Maria Pereira +4 more
core +1 more source
Therapeutic tools for oral candidiasis : current and new antifungal drugs [PDF]
, 2019 Candidiasis is one of the most common opportunistic oral infections that presents different acute and chronic clinical presentations with diverse diagnostic and therapeutic approaches.
Eraso Barrio, Elena +6 more
core +1 more source